These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 29703251)
1. Allogeneic transplantation of programmable cells of monocytic origin (PCMO) improves angiogenesis and tissue recovery in critical limb ischemia (CLI): a translational approach. Berndt R; Hummitzsch L; Heß K; Albrecht M; Zitta K; Rusch R; Sarras B; Bayer A; Cremer J; Faendrich F; Groß J Stem Cell Res Ther; 2018 Apr; 9(1):117. PubMed ID: 29703251 [TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of mouse bone marrow and adipose tissue mesenchymal stem cells for critical limb ischemia cell therapy. Nammian P; Asadi-Yousefabad SL; Daneshi S; Sheikhha MH; Tabei SMB; Razban V Stem Cell Res Ther; 2021 Jan; 12(1):58. PubMed ID: 33436054 [TBL] [Abstract][Full Text] [Related]
3. Concise Review: Cell Therapy for Critical Limb Ischemia: An Integrated Review of Preclinical and Clinical Studies. Qadura M; Terenzi DC; Verma S; Al-Omran M; Hess DA Stem Cells; 2018 Feb; 36(2):161-171. PubMed ID: 29226477 [TBL] [Abstract][Full Text] [Related]
4. The programmable cell of monocytic origin (PCMO): a potential adult stem/progenitor cell source for the generation of islet cells. Ungefroren H; Fändrich F Adv Exp Med Biol; 2010; 654():667-82. PubMed ID: 20217519 [TBL] [Abstract][Full Text] [Related]
5. Inflammation is associated with a reduced number of pro-angiogenic Tie-2 monocytes and endothelial progenitor cells in patients with critical limb ischemia. Dopheide JF; Geissler P; Rubrech J; Trumpp A; Zeller GC; Bock K; Dorweiler B; Dünschede F; Münzel T; Radsak MP; Espinola-Klein C Angiogenesis; 2016 Jan; 19(1):67-78. PubMed ID: 26462497 [TBL] [Abstract][Full Text] [Related]
6. Pluripotency gene expression and growth control in cultures of peripheral blood monocytes during their conversion into programmable cells of monocytic origin (PCMO): evidence for a regulatory role of autocrine activin and TGF-β. Ungefroren H; Hyder A; Hinz H; Groth S; Lange H; El-Sayed KM; Ehnert S; Nüssler AK; Fändrich F; Gieseler F PLoS One; 2015; 10(2):e0118097. PubMed ID: 25707005 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic angiogenesis using zinc oxide nanoflowers for the treatment of hind limb ischemia in a rat model. Barui AK; Nethi SK; Basuthakur P; Jhelum P; Bollu VS; Reddy BR; Chakravarty S; Patra CR Biomed Mater; 2021 Mar; 16(4):. PubMed ID: 33657534 [TBL] [Abstract][Full Text] [Related]
8. Molecular imaging of the paracrine proangiogenic effects of progenitor cell therapy in limb ischemia. Ryu JC; Davidson BP; Xie A; Qi Y; Zha D; Belcik JT; Caplan ES; Woda JM; Hedrick CC; Hanna RN; Lehman N; Zhao Y; Ting A; Lindner JR Circulation; 2013 Feb; 127(6):710-9. PubMed ID: 23307829 [TBL] [Abstract][Full Text] [Related]
9. Cell therapy in critical limb ischemia: A comprehensive analysis of two cell therapy products. Tournois C; Pignon B; Sevestre MA; Al-Rifai R; Creuza V; Poitevin G; François C; Nguyen P Cytotherapy; 2017 Feb; 19(2):299-310. PubMed ID: 27914820 [TBL] [Abstract][Full Text] [Related]
10. Beneficial effects of VEGF secreted from stromal cells in supporting endothelial cell functions: therapeutic implications for critical limb ischemia. Cobellis G; Maione C; Botti C; Coppola A; Silvestroni A; Lillo S; Schiavone V; Molinari AM; Sica V Cell Transplant; 2010; 19(11):1425-37. PubMed ID: 20587143 [TBL] [Abstract][Full Text] [Related]
11. Nanoscale strategies: treatment for peripheral vascular disease and critical limb ischemia. Tu C; Das S; Baker AB; Zoldan J; Suggs LJ ACS Nano; 2015; 9(4):3436-52. PubMed ID: 25844518 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of ixmyelocel-T, an expanded autologous multicellular therapy for treatment of ischemic cardiovascular diseases. Ledford KJ; Murphy N; Zeigler F; Bartel RL; Tubo R Stem Cell Res Ther; 2015 Mar; 6(1):25. PubMed ID: 25889271 [TBL] [Abstract][Full Text] [Related]